Blueprint Medicines Corp
NASDAQ:BPMC

Watchlist Manager
Blueprint Medicines Corp Logo
Blueprint Medicines Corp
NASDAQ:BPMC
Watchlist
Price: 94.63 USD 0.81% Market Closed
Market Cap: 6B USD
Have any thoughts about
Blueprint Medicines Corp?
Write Note

Intrinsic Value

The intrinsic value of one BPMC stock under the Base Case scenario is 94.54 USD. Compared to the current market price of 94.63 USD, Blueprint Medicines Corp is Fairly Valued.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BPMC Intrinsic Value
94.54 USD
Fairly Valued
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Blueprint Medicines Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BPMC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BPMC?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Blueprint Medicines Corp

Provide an overview of the primary business activities
of Blueprint Medicines Corp.

What unique competitive advantages
does Blueprint Medicines Corp hold over its rivals?

What risks and challenges
does Blueprint Medicines Corp face in the near future?

Has there been any significant insider trading activity
in Blueprint Medicines Corp recently?

Summarize the latest earnings call
of Blueprint Medicines Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Blueprint Medicines Corp.

Provide P/S
for Blueprint Medicines Corp.

Provide P/E
for Blueprint Medicines Corp.

Provide P/OCF
for Blueprint Medicines Corp.

Provide P/FCFE
for Blueprint Medicines Corp.

Provide P/B
for Blueprint Medicines Corp.

Provide EV/S
for Blueprint Medicines Corp.

Provide EV/GP
for Blueprint Medicines Corp.

Provide EV/EBITDA
for Blueprint Medicines Corp.

Provide EV/EBIT
for Blueprint Medicines Corp.

Provide EV/OCF
for Blueprint Medicines Corp.

Provide EV/FCFF
for Blueprint Medicines Corp.

Provide EV/IC
for Blueprint Medicines Corp.

Show me price targets
for Blueprint Medicines Corp made by professional analysts.

What are the Revenue projections
for Blueprint Medicines Corp?

How accurate were the past Revenue estimates
for Blueprint Medicines Corp?

What are the Net Income projections
for Blueprint Medicines Corp?

How accurate were the past Net Income estimates
for Blueprint Medicines Corp?

What are the EPS projections
for Blueprint Medicines Corp?

How accurate were the past EPS estimates
for Blueprint Medicines Corp?

What are the EBIT projections
for Blueprint Medicines Corp?

How accurate were the past EBIT estimates
for Blueprint Medicines Corp?

Compare the revenue forecasts
for Blueprint Medicines Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Blueprint Medicines Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Blueprint Medicines Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Blueprint Medicines Corp compared to its peers.

Compare the P/E ratios
of Blueprint Medicines Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Blueprint Medicines Corp with its peers.

Analyze the financial leverage
of Blueprint Medicines Corp compared to its main competitors.

Show all profitability ratios
for Blueprint Medicines Corp.

Provide ROE
for Blueprint Medicines Corp.

Provide ROA
for Blueprint Medicines Corp.

Provide ROIC
for Blueprint Medicines Corp.

Provide ROCE
for Blueprint Medicines Corp.

Provide Gross Margin
for Blueprint Medicines Corp.

Provide Operating Margin
for Blueprint Medicines Corp.

Provide Net Margin
for Blueprint Medicines Corp.

Provide FCF Margin
for Blueprint Medicines Corp.

Show all solvency ratios
for Blueprint Medicines Corp.

Provide D/E Ratio
for Blueprint Medicines Corp.

Provide D/A Ratio
for Blueprint Medicines Corp.

Provide Interest Coverage Ratio
for Blueprint Medicines Corp.

Provide Altman Z-Score Ratio
for Blueprint Medicines Corp.

Provide Quick Ratio
for Blueprint Medicines Corp.

Provide Current Ratio
for Blueprint Medicines Corp.

Provide Cash Ratio
for Blueprint Medicines Corp.

What is the historical Revenue growth
over the last 5 years for Blueprint Medicines Corp?

What is the historical Net Income growth
over the last 5 years for Blueprint Medicines Corp?

What is the current Free Cash Flow
of Blueprint Medicines Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Blueprint Medicines Corp.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Blueprint Medicines Corp

Current Assets 903.5m
Cash & Short-Term Investments 763.6m
Receivables 85.1m
Other Current Assets 54.9m
Non-Current Assets 300m
Long-Term Investments 104.9m
PP&E 109m
Other Non-Current Assets 86.1m
Current Liabilities 243.8m
Accounts Payable 4.9m
Accrued Liabilities 133.2m
Other Current Liabilities 105.7m
Non-Current Liabilities 639.5m
Long-Term Debt 338.7m
Other Non-Current Liabilities 300.9m
Efficiency

Earnings Waterfall
Blueprint Medicines Corp

Revenue
434.4m USD
Cost of Revenue
-13m USD
Gross Profit
421.4m USD
Operating Expenses
-697.4m USD
Operating Income
-276m USD
Other Expenses
147.9m USD
Net Income
-128.1m USD

Free Cash Flow Analysis
Blueprint Medicines Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Blueprint Medicines reported robust growth for its flagship drug, AYVAKIT, generating $128.2 million in Q3, a 137% increase year-over-year. The company raised its 2024 revenue guidance to between $475 million and $480 million, reflecting strong patient additions and compliance. AYVAKIT is on track to exceed a $2 billion revenue opportunity. International markets are also performing well, and cash burn is expected to decline significantly. Blueprint is focused on expanding its mast cell therapy portfolio, including upcoming studies for BLU-808 and elenestinib, while enhancing patient outreach initiatives to solidify its market position and drive sustainable growth into 2025.

What is Earnings Call?
Fundamental Scores

BPMC Profitability Score
Profitability Due Diligence

Blueprint Medicines Corp's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
31/100
Profitability
Score

Blueprint Medicines Corp's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

BPMC Solvency Score
Solvency Due Diligence

Blueprint Medicines Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Average D/E
42/100
Solvency
Score

Blueprint Medicines Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BPMC Price Targets Summary
Blueprint Medicines Corp

Wall Street analysts forecast BPMC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BPMC is 128.09 USD with a low forecast of 81.81 USD and a high forecast of 175.35 USD.

Lowest
Price Target
81.81 USD
14% Downside
Average
Price Target
128.09 USD
35% Upside
Highest
Price Target
175.35 USD
85% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BPMC?

Click here to dive deeper.

Dividends

Blueprint Medicines Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for BPMC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

BPMC Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

BPMC News

Other Videos

Profile

Blueprint Medicines Corp Logo
Blueprint Medicines Corp

Country

United States of America

Industry

Biotechnology

Market Cap

6B USD

Dividend Yield

0%

Description

Blueprint Medicines Corp. is a precision therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 495 full-time employees. The company went IPO on 2015-04-30. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). The company is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The firm is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.

Contact

MASSACHUSETTS
Cambridge
45 Sidney St
+16173747580.0
www.blueprintmedicines.com

IPO

2015-04-30

Employees

495

Officers

President, CEO & Director
Ms. Kathryn Haviland M.B.A.
Co-Founder & Director
Mr. Alexis A. Borisy A.M.
Chief Financial Officer
Mr. Michael Landsittel
Chief Operating Officer
Ms. Christina Rossi M.B.A.
Chief Scientific Officer
Dr. Percy H. Carter M.B.A., Ph.D.
President of Research & Development
Dr. Fouad Namouni M.D.
Show More
Senior VP, Finance & Principal Accounting Officer
Ms. Ariel Hurley
Senior Director & Head of Investor Relations
Jenna Cohen
Executive VP, Chief Legal & Compliance Officer and Secretary
Ms. Tracey L. McCain Esq.
Chief People Officer
Ms. Debra Durso-Bumpus
Show Less

See Also

Discover More
What is the Intrinsic Value of one BPMC stock?

The intrinsic value of one BPMC stock under the Base Case scenario is 94.54 USD.

Is BPMC stock undervalued or overvalued?

Compared to the current market price of 94.63 USD, Blueprint Medicines Corp is Fairly Valued.

Back to Top